Fluoropyrimidine and platinum toxicity pharmacogenetics: An umbrella review of systematic reviews and meta-analyses

Pharmacogenomics

Volumn 17, Issue 4, 2016, Pages 435-451

  Campbell, Jared M ^a   Bateman, Emma ^b   Peters, Micah D J ^a   Bowen, Joanne M ^b   Keefe, Dorothy M ^b   Stephenson, Matthew D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

adverse events; cancer; chemotherapy; fluoropyrimidine; FU; personalized medicine; pharmacogenetics; pharmacogenomics; platinum; toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; PLATINUM COMPLEX; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; OXALIPLATIN;

3' UNTRANSLATED REGION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; DIARRHEA; DPYD GENE; DRUG EFFECT; DRUG SAFETY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MTHFR GENE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TYMS GENE; ANALOGS AND DERIVATIVES; GENETIC POLYMORPHISM; GENETICS; LITERATURE; META ANALYSIS (TOPIC); NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FLUOROURACIL; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; REVIEW LITERATURE AS TOPIC;

EID: 84960902404     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.180     Document Type: Review

References (47)

1. Scartozzi M, Maccaroni E, Giampieri R et al. 5-fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics 12(2), 251-265 (2011).
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5), 330-338 (2003).
3. Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 34(4), 1531-1535 (2014).
4. Chau I, Norman AR, Cunningham D et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol. 16(4), 549-557 (2005).
5. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 7(4), 288-323 (2002).
6. Grem JL. 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs 18(4), 299-313 (2000).
7. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352(26), 2696-2704 (2005).
8. Levy E, Piedbois P, Buyse M et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 16(11), 3537-3541 (1998).
9. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale Phase III trial. Cancer 75(1), 11-17 (1995).
10. Tepper JE, O'connell MJ, Petroni GR et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J. Clin. Oncol. 15(5), 2030-2039 (1997).
11. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur. J. Cancer 34(12), 1871-1875 (1998).
12. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann. Oncol. 15(11), 1585-1595 (2004).
13. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62(17), 4899-4902 (2002).
14. Hato SV, Khong A, De Vries IJM, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin. Cancer Res. 20(11), 2831-2837 (2014).
15. Stojanovska V, Sakkal S, Nurgali K. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am. J. Physiol. 308(4), G223-G232 (2015).
16. Mcwhinney SR, Goldberg RM, Mcleod HL. Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther. 8(1), 10-16 (2009).
17. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17(10), 3455-3468 (2011).
18. Gross E, Busse B, Riemenschneider M et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE 3(12), e4003 (2008).
19. Joerger M, Burgers SA, Baas P et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: A prospective clinical study. Cancer 118(9), 2466-2475 (2012).
20. Li QF, Yao RY, Liu KW, Lv HY, Jiang T, Liang J. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J. Korean Med. Sci. 25(6), 846-852 (2010).
21. N-NWGORIA Studies, Chanock SJ, Manolio T et al. Replicating genotype-phenotype associations. Nature 447(7145), 655-660 (2007).
22. Campbell JM, Peters MDJ. The association of chemotherapyinduced toxicities with germline polymorphisms: An umbrella review of systematic reviews and meta-analyses. JBISRIR 12(10), 40-46 (2014).
23. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int. J. Evid. Based Healthc. 13(3), 132-140 (2015).
24. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet. Genomics 22(4), 290-304 (2012).
25. Rosmarin D, Palles C, Church D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32(10), 1031-1039 (2014).
26. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidinerelated toxicity: A meta-analysis. Pharmacogenomics 14(11), 1255-1272 (2013).
27. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: A systematic review. BMC Gastroenterol. 12, 137 (2012).
28. Peng Z, Wang Q, Gao J et al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: A systematic review and meta-analysis. Cancer Chemother. Pharmacol. 72(2), 305-314 (2013).
29. Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinumbased chemotherapy in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis. Tumour Biol. 35(4), 2905-2921 (2014).
30. Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol. 27(33), 5519-5528 (2009).
31. Lee A, Ezzeldin H, Fourie J, Diasio R. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin. Adv. Hematol. Oncol. 2(8), 527-532 (2004).
32. Wei X, Mcleod HL, Mcmurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98(3), 610-615 (1996).
33. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17(10), 3455-3468 (2011).
34. Caudle KE, Thorn CF, Klein TE et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94(6), 640-645 (2013).
35. Deenen MJ, Cats A, Mandigers CM et al. Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency. Ned. Tijdschr. Geneeskd. 156(48), A4934 (2012).
36. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6(10), 1653-1664 (1988).
37. Papamichael D. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. Stem Cells 18(3), 166-175 (2000).
38. Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracilbased chemotherapy toxicity. Expert Opin. Drug Metabol. Toxicol. 11(5), 811-821 (2015).
39. Mandola MV, Stoehlmacher J, Muller-Weeks S et al. A novel single nucleotide polymorphism within the 5 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63(11), 2898-2904 (2003).
40. Zhang QA, Zhao YP, Liao QA et al. Associations between gene polymorphisms of thymidylate synthase with its protein expression and chemosensitivity to 5-fluorouracil in pancreatic carcinoma cells. Chinese Med. J. 124(2), 262-267 (2011).
41. Van Kuilenburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6(12), 4705-4712 (2000).
42. Vreken P, Van Kuilenburg AB, Meinsma R, Van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum. Genet. 101(3), 333-338 (1997).
43. Caudle KE, Thorn CF, Klein TE et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94(6), 640-645 (2013).
44. Suzen HS, Yuce N, Guvenc G, Duydu Y, Erke T. TYMS and DPYD polymorphisms in a Turkish population. Eur. J. Clin. Pharmacol. 61(12), 881-885 (2005).
45. Shamseer L, Moher D, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349, g7647 (2015).
46. Wood L, Egger M, Gluud LL et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336(7644), 601-605 (2008).
47. Balk EM, Bonis PA, Moskowitz H et al. Correlation of quality measures with estimates of treatment effect in metaanalyses of randomized controlled trials. JAMA 287(22), 2973-2982 (2002).